The gene-editing company said it will use the new funding in part to advance its efforts to bring back the extinct dodo bird.

The firm said that it has been awarded funding to support the development of its cancer detection technology and a test for oropharyngeal squamous cell carcinoma.

The company is developing biological foundation models to be used in drug discovery and other gene expression-based applications. 

The Bureau of Industry and Security said these firms "pose an unacceptable risk of using or diverting US origin items" for army-related activities.

The Cambridge, UK-based multiomics drug discovery company previously raised around $13.6 million in Series A funding in 2022.

Last week, GenomeWeb’s readers were most interested in MGI Tech's launch of the T7+ ultra-high-throughput sequencing platform.

Researchers tallied pathogenic or likely pathogenic germline BRCA1/2 variants within and across ethnicity groups in more than 2,400 diverse, unselected breast cancer patients.

The US-based molecular diagnostic laboratory's PCR-based test detects persistent human papillomavirus infection, a main cause of oropharyngeal cancer.

New products and services recently posted on GenomeWeb.

The firm acquired intellectual property from Mammoth Biosciences that will reduce the speed and cost of its in-development point-of-care solution.

The medical services company will market the test to the senior living communities it serves across 20 states with exclusive rights to distribute the assay in Florida.

The company intends to use the net proceeds for working capital and general corporate purposes.

News items for the week of Sept. 8, 2025.

With the new certification, the full portfolio of QiaStat-Dx qPCR-based multiplex panels and instruments is now CE-IVDR certified.

The company's flagship product is its cloud-based Weave software platform for handling multiomics spatial assay data.

The nonexclusive license potentially broadens VedaBio's platform while making it simpler and more cost-effective.

Researchers came up with a computational model for exploring extrachromosomal DNA contributions to glioblastoma evolution over time, including roles for amplified oncogenes.